Can your own stem cells ward off COVID-19?

NCT ID NCT04349631

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether five infusions of a person's own stem cells (HB-adMSCs) could prevent COVID-19 symptoms and hospitalization in 51 high-risk adults, such as those over 65 or with underlying health conditions. Participants had previously banked their cells at Hope Biosciences. The goal was to see if the treatment could boost the immune system and reduce severe illness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

51 people

The number who actually took part.

Started

Apr 2020

Finished

Nov 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet the criteria for 1,2, OR 3, AND 4-7 to be eligible. 1. Men, and women 65 years of age or older (according to CDC provisions) OR 2. Participant works in healthcare facility or other well characterized high-risk environment OR 3. Has underlying conditions including but not limited to cardiopathies, diabetes mellitus, cancer, COPD, asthma or any other systemic autoimmune disease. 4. Subject must have previously banked their cells at Hope Biosciences 5. No signs or symptoms of infection, including but not limited to, body temperature \>100 F and pulse rate \> 100 BPM. 6. Subject provides written informed consent prior to initiation of any study procedures. 7. Agrees to the collection of venous blood per protocol. 8. Agrees to conformational testing for SARS-CoV-2 before end of study. Exclusion Criteria: Subjects must not have any of the following criteria to be eligible. 1. Women who are pregnant or lactating, or those who are not pregnant but do not take effective contraceptive measures 2. Patients who are participating in other clinical trials or have intake of investigational drug within the previous 30 days; 3. Inability to provide informed consent or to comply with test requirements; 4. Any medical disease or condition that, in the opinion of the site PI or sub-investigator, precludes study participation. Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial. 5. Patients who have received a stem cell treatment within one year. 6. Receipt of any other SARS-CoV-2 or other experimental coronavirus vaccine at any time prior to or during the study. 7. Patient currently or recently symptomatic for COVID-19 or anyone with COVID-19 associated symptoms within the past 30-days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hope Biosciences Stem Cell Research Foundation

    Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.